1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Angiotensin Converting Enzyme (ACE) Inhibitors -Pipeline Insights, 2016


DelveInsight’s, “Angiotensin Converting Enzyme (ACE) Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Angiotensin Converting Enzyme (ACE) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Angiotensin Converting Enzyme (ACE) Inhibitors. DelveInsight’s Report also assesses the Angiotensin Converting Enzyme (ACE) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Angiotensin Converting Enzyme (ACE) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Angiotensin Converting Enzyme (ACE) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Angiotensin Converting Enzyme (ACE) Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Angiotensin Converting Enzyme (ACE) Inhibitors -Pipeline Insights, 2016

- Angiotensin Converting Enzyme (ACE) Inhibitors Overview
- Angiotensin Converting Enzyme (ACE) Inhibitors Disease Associated
- Angiotensin Converting Enzyme (ACE) Inhibitors Pipeline Therapeutics
- Angiotensin Converting Enzyme (ACE) Inhibitors Therapeutics under Development by Companies
- Angiotensin Converting Enzyme (ACE) Inhibitors Filed and Phase III Products
- Comparative Analysis
- Angiotensin Converting Enzyme (ACE) Inhibitors Phase II Products
- Comparative Analysis
- Angiotensin Converting Enzyme (ACE) Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- Angiotensin Converting Enzyme (ACE) Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Angiotensin Converting Enzyme (ACE) Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Angiotensin Converting Enzyme (ACE) Inhibitors - Discontinued Products
- Angiotensin Converting Enzyme (ACE) Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for Angiotensin Converting Enzyme (ACE) Inhibitors
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Angiotensin Converting Enzyme (ACE) Inhibitors by Therapy Area, 2016
- Number of Products under Development for Angiotensin Converting Enzyme (ACE) Inhibitors, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Monotherapy Products
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Combination Products
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Route of Administration
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Stage and Route of Administration
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Molecule Type
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Stage and Molecule Type
- Angiotensin Converting Enzyme (ACE) Inhibitors Therapeutics - Discontinued Products
- Angiotensin Converting Enzyme (ACE) Inhibitors Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Angiotensin Converting Enzyme (ACE) Inhibitors by Therapy Area, 2016
- Number of Products under Development for Angiotensin Converting Enzyme (ACE) Inhibitors, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Monotherapy Products
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Combination Products
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Route of Administration
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Stage and Route of Administration
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Molecule Type
- Angiotensin Converting Enzyme (ACE) Inhibitors Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Molecular Biology Enzymes and Kits & Reagents Market by Product, Application, End User - Trends & Global Forecasts to 2021

Molecular Biology Enzymes and Kits & Reagents Market by Product, Application, End User - Trends & Global Forecasts to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The molecular biology enzymes and kits & reagents market is projected to reach USD 12.69 billion by 2021 from USD 5.77 billion in 2016, growing at a CAGR of 17.1% during the forecast period of 2016 to ...

Global Food Enzyme Market

Global Food Enzyme Market

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The growing demand for processed foods and increasing health consciousness in the people is driving the food & beverages industry which inturn is driving the food enzymes market. Food enzymes are a majo ...

North America Industrial Enzymes Market - Growth, Trends, and Forecasts (2016-2021)

North America Industrial Enzymes Market - Growth, Trends, and Forecasts (2016-2021)

  • $ 3850
  • Industry report
  • September 2016
  • by Mordor Intelligence LLP

The North American industrial enzymes market was valued at USD XX.XX million in  2016 and is projected to reach USD XX.XX million by 2021 at a CAGR of XX.XX% during the forecast period from 2016 to 2021. ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.